Form 4: ALX Oncology Director Granted Stock Options
Director Stock Option Grant
ALX Oncology Holdings Inc. Director Daniel J. Curran was granted 40,400 stock options with a $0.615 exercise price, vesting monthly over three years.
Summary
- Director Daniel J. Curran of ALX Oncology Holdings Inc. (ALXO) was granted 40,400 stock options.
- The options have an exercise price of $0.615 per share.
- The options will vest in 36 equal monthly installments, starting on September 12, 2025.
- The options are set to expire on August 11, 2035.
Sentiment
Score: 7
Explanation: The grant of stock options to a director is a positive sign of alignment between management and shareholder interests, incentivizing long-term performance. It's a routine compensation event, not indicative of major operational shifts.
Positives
- Granting stock options to a director aligns their interests with shareholders, incentivizing long-term company performance.
- The options have a 10-year expiration period, providing a long window for potential value realization.
Future Outlook
The stock options granted to Director Daniel J. Curran are set to vest in 36 equal monthly installments beginning September 12, 2025, indicating a long-term incentive structure for management.
Industry Context
This routine equity grant to a director is a common practice in the biotechnology and pharmaceutical industries, used to attract and retain talent and align executive interests with long-term shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Structure | Grant of 40,400 stock options to Director Daniel J. Curran as part of his compensation, aligning his interests with long-term shareholder value. | 08/12/2025 | Enhances director's vested interest in the company's long-term stock performance. |
Related Party Transactions
- Director Daniel J. Curran, a related party, was granted 40,400 stock options by ALX Oncology Holdings Inc.
Stakeholder Impact
- Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance.
- Employees: No direct impact on general employees is indicated by this filing.
- Management: Strengthens the incentive structure for the director.
Next Steps
- The granted stock options will begin vesting in 36 equal monthly installments starting September 12, 2025.
Key Dates
| Date | Description |
|---|---|
| 08/12/2025 | Date of stock option grant to Director Daniel J. Curran. |
| 09/12/2025 | Start date for the 36 equal monthly vesting installments of the stock options. |
| 08/13/2025 | Filing date of the Form 4. |
| 08/11/2035 | Expiration date of the granted stock options. |
Keywords
ALX Oncology Holdings Inc., ALXO, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Corporate Governance, Biotechnology, Oncology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.